Stockreport

Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Maze Therapeutics, Inc.  (MAZE) 
PDF First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and chronic kid [Read more]